153 related articles for article (PubMed ID: 20884743)
21. TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions.
Porcel JM; Palma R; Bielsa S; Esquerda A; Gatius S; Matias-Guiu X; Salud A
Respirology; 2015 Jul; 20(5):831-3. PubMed ID: 25873201
[TBL] [Abstract][Full Text] [Related]
22. Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer.
Zhong J; Li X; Bai H; Zhao J; Wang Z; Duan J; An T; Wu M; Wang Y; Wang S; Wang J
Cytopathology; 2016 Dec; 27(6):433-443. PubMed ID: 27060609
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer.
Su WP; Chen YT; Lai WW; Lin CC; Yan JJ; Su WC
Lung Cancer; 2011 Jan; 71(1):28-33. PubMed ID: 20430468
[TBL] [Abstract][Full Text] [Related]
24. Slug regulates E-cadherin expression in metastatic adenocarcinoma cells isolated from pleural fluid.
Li XN; Fang CQ; Wang YL; Wang XR; Wang EH; Li JH
Diagn Cytopathol; 2013 Jan; 41(1):9-14. PubMed ID: 21656704
[TBL] [Abstract][Full Text] [Related]
25. Vinorelbine is effective for the malignant pleural effusion associated with lung cancer in mice.
Cui R; Yoshioka M; Takahashi F; Ishida H; Iwakami S; Takahashi K
Anticancer Res; 2008; 28(3A):1633-9. PubMed ID: 18630520
[TBL] [Abstract][Full Text] [Related]
26. CD39 identifies a specific CD8 + T cell population in lung adenocarcinoma-related metastatic pleural effusion.
Lv LL; Wang HB; Zhang YX; Zhai JW; Shen Y; Qu QX; Chen C
BMC Immunol; 2023 Dec; 24(1):53. PubMed ID: 38087217
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutical effects of pleural injecting recombinant human endostain to
malignant pleural effusion nude mice model].
Zhou M; Li M; Yang H; Hu C
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):266-71. PubMed ID: 25975296
[TBL] [Abstract][Full Text] [Related]
28. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
29. Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion.
Magkouta S; Pappas A; Moschos C; Vazakidou ME; Psarra K; Kalomenidis I
Oncotarget; 2016 Apr; 7(15):20249-59. PubMed ID: 26959120
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
32. Mast cells mediate malignant pleural effusion formation.
Giannou AD; Marazioti A; Spella M; Kanellakis NI; Apostolopoulou H; Psallidas I; Prijovich ZM; Vreka M; Zazara DE; Lilis I; Papaleonidopoulos V; Kairi CA; Patmanidi AL; Giopanou I; Spiropoulou N; Harokopos V; Aidinis V; Spyratos D; Teliousi S; Papadaki H; Taraviras S; Snyder LA; Eickelberg O; Kardamakis D; Iwakura Y; Feyerabend TB; Rodewald HR; Kalomenidis I; Blackwell TS; Agalioti T; Stathopoulos GT
J Clin Invest; 2015 Jun; 125(6):2317-34. PubMed ID: 25915587
[TBL] [Abstract][Full Text] [Related]
33. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
34. Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion.
Vazakidou ME; Magkouta S; Moschos C; Kalomenidis I
Respirology; 2014 Feb; 19(2):290-292. PubMed ID: 23819792
[TBL] [Abstract][Full Text] [Related]
35. Fructose-bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis.
Kawai K; Uemura M; Munakata K; Takahashi H; Haraguchi N; Nishimura J; Hata T; Matsuda C; Ikenaga M; Murata K; Mizushima T; Yamamoto H; Doki Y; Mori M
Int J Oncol; 2017 Feb; 50(2):525-534. PubMed ID: 28000858
[TBL] [Abstract][Full Text] [Related]
36. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.
Xiang Z; Deng X; He W; Yang Q; Ni L; Dehghan Shasaltaneh M; Maghsoudloo M; Yang G; Wu J; Imani S; Wen Q
Ann Med; 2022 Dec; 54(1):1357-1371. PubMed ID: 35543207
[TBL] [Abstract][Full Text] [Related]
37. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
38. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression.
Chang YC; Chan YC; Chang WM; Lin YF; Yang CJ; Su CY; Huang MS; Wu ATH; Hsiao M
Cancer Lett; 2017 Sep; 403():28-36. PubMed ID: 28610954
[TBL] [Abstract][Full Text] [Related]
39. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Psallidas I; Karabela SP; Moschos C; Sherrill TP; Kollintza A; Magkouta S; Theodoropoulou P; Roussos C; Blackwell TS; Kalomenidis I; Stathopoulos GT
Mol Cancer; 2010 Mar; 9():56. PubMed ID: 20219102
[TBL] [Abstract][Full Text] [Related]
40. Up-regulated HMGB1 in the pleural effusion of non-small cell lung cancer (NSCLC) patients reduces the chemosensitivity of NSCLC cells.
Ma Y; Kang S; Wu X; Han B; Jin Z; Guo Z
Tumori; 2018 Oct; 104(5):338-343. PubMed ID: 28885675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
